MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Merck & Co Inc.

Avatud

SektorTervishoid

78.97 0.79

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

77.77

Max

79.93

Põhinäitajad

By Trading Economics

Sissetulek

583M

3.7B

Müük

-1B

16B

P/E

Sektori keskmine

11.55

57.333

Aktsiakasum

1.72

Dividenditootlus

4.15

Kasumimarginaal

23.963

Töötajad

73,000

EBITDA

1.3B

6.9B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+35.27% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

4.15%

2.63%

Järgmine dividendimakse kuupäev

7. juuli 2025

Järgmine aktsia dividendi kuupäev (ex-date)

16. juuni 2025

Turustatistika

By TradingEconomics

Turukapital

-56B

196B

Eelmine avamishind

78.18

Eelmine sulgemishind

78.97

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Merck & Co Inc. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. apr 2025, 18:18 UTC

Suurimad hinnamuutused turgudel

Pharma Shares Reverse Losses After Tariff Pause

9. apr 2025, 09:39 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4. veebr 2025, 12:33 UTC

Tulu

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4. veebr 2025, 11:57 UTC

Tulu

Merck 4Q Sales Increase Results in Swing to Profit

24. apr 2025, 20:08 UTC

Tulu

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24. apr 2025, 16:05 UTC

Peamised uudised
Tulu

Merck Cuts 2025 Outlook on Tariffs, Charges -- Update

24. apr 2025, 14:36 UTC

Market Talk
Tulu

Merck's Challenges with Gardasil in China Continue -- Market Talk

24. apr 2025, 14:10 UTC

Market Talk
Tulu

Merck's Mostly Steady Guidance Sees Current Tariffs Being Absorbed -- Market Talk

24. apr 2025, 11:35 UTC

Tulu

Merck Lowers Earnings Guidance and Says Tariffs Will Hit Margins -- Barrons.com

24. apr 2025, 10:58 UTC

Peamised uudised
Tulu

Merck 1Q Net Up, But 2025 Adj EPS View Cut on Tariffs, Charges

24. apr 2025, 10:55 UTC

Tulu

Merck Stock Rises After Earnings Even as Keytruda Sales Miss Estimates. Here's Why. -- Barrons.com

24. apr 2025, 10:31 UTC

Tulu

Merck: 2025 Outlook Absorbs Estimated $200 Million Additional Costs for Tariffs Implemented to Date >MRK

24. apr 2025, 10:30 UTC

Tulu

Merck 1Q Keytruda Sales $7.21B >MRK

24. apr 2025, 10:30 UTC

Tulu

Merck 1Q Pharmaceutical Sales $13.64B >MRK

24. apr 2025, 10:30 UTC

Tulu

Merck 1Q Keytruda Sales Up 4% >MRK

24. apr 2025, 10:30 UTC

Tulu

Merck 1Q Januvia/Janumet Sales Up 19% >MRK

24. apr 2025, 10:30 UTC

Tulu

Merck 1Q Pharmaceutical Sales Down 3% >MRK

24. apr 2025, 10:30 UTC

Tulu

Merck 1Q Gardasil/Gardasil 9 Sales $1.33B >MRK

24. apr 2025, 10:30 UTC

Tulu

Merck 1Q Januvia/Janumet Sales $796M >MRK

24. apr 2025, 09:13 UTC

Kuumad aktsiad

Stocks to Watch Thursday: IBM, Tesla, Chipotle -- WSJ

24. märts 2025, 05:00 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5. märts 2025, 19:42 UTC

Peamised uudised

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5. märts 2025, 10:30 UTC

Peamised uudised

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5. veebr 2025, 12:00 UTC

Peamised uudised

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4. veebr 2025, 14:48 UTC

Tulu

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4. veebr 2025, 11:51 UTC

Tulu

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4. veebr 2025, 11:50 UTC

Tulu

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4. veebr 2025, 11:31 UTC

Tulu

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4. veebr 2025, 11:31 UTC

Tulu

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4. veebr 2025, 11:31 UTC

Tulu

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

Võrdlus sarnastega

Hinnamuutus

Merck & Co Inc. Prognoos

Hinnasiht

By TipRanks

35.27% tõus

12 kuu keskmine prognoos

Keskmine 108 USD  35.27%

Kõrge 138 USD

Madal 85 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Merck & Co Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

18 ratings

11

Osta

7

Hoia

0

Müü

Tehniline skoor

By Trading Central

77.85 / 80.02Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.